Literature DB >> 15748877

The effect of glutamate receptor blockers on glutamate release following spinal cord injury. Lack of evidence for an ongoing feedback cascade of damage --> glutamate release --> damage --> glutamate release --> etc.

David J McAdoo1, Michael G Hughes, Linghui Nie, Bhavin Shah, Cannon Clifton, Steven Fullwood, Claire E Hulsebosch.   

Abstract

It is widely hypothesized that excitotoxicity of released glutamate following a CNS insult is propagated by the cyclic cascade: glutamate release --> damage --> glutamate release --> further damage --> etc. We tested this hypothesis by determining the effects of attempting to interrupt the loop by administering glutamate receptor antagonists and Na(+)-channel blockers on glutamate release following spinal cord injury (SCI). The effects of administering the NMDA receptor blockers MK-801 and memantine, the AMPA/kainate receptor blockers NBQX and GYKI 52466, the AMPA receptor desensitization blocker cyclothiazide and the sodium channel blockers riluzole, mexiletine and QX-314 on post-SCI were determined. Agents were administered into the site of injury by direct injection, by microdialysis or systemically. None of these agents had an appreciable effect on glutamate release following SCI. Thus, it is unlikely that the above cascade produces significant secondary glutamate release and ongoing damage following SCI, although such cascades may worsen other CNS insults. We attribute our results to overwhelming effects of much greater release by direct mechanical damage and reversal of transport following SCI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15748877     DOI: 10.1016/j.brainres.2005.01.024

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

Review 1.  Spinal cord injury: a systematic review of current treatment options.

Authors:  David W Cadotte; Michael G Fehlings
Journal:  Clin Orthop Relat Res       Date:  2011-03       Impact factor: 4.176

2.  Expansion of formalin-evoked Fos-immunoreactivity in rats with a spinal cord injury.

Authors:  Daniel A Castellanos; Linda A Daniels; Mena P Morales; Aldric T Hama; Jacqueline Sagen
Journal:  Neurosci Res       Date:  2007-05-03       Impact factor: 3.304

Review 3.  A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury.

Authors:  Brian K Kwon; Elena Okon; Jessica Hillyer; Cody Mann; Darryl Baptiste; Lynne C Weaver; Michael G Fehlings; Wolfram Tetzlaff
Journal:  J Neurotrauma       Date:  2010-04-14       Impact factor: 5.269

4.  Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury.

Authors:  J Marc Simard; Orest Tsymbalyuk; Kaspar Keledjian; Alexander Ivanov; Svetlana Ivanova; Volodymyr Gerzanich
Journal:  Exp Neurol       Date:  2011-12-08       Impact factor: 5.330

5.  Glutamate-induced losses of oligodendrocytes and neurons and activation of caspase-3 in the rat spinal cord.

Authors:  G-Y Xu; S Liu; M G Hughes; D J McAdoo
Journal:  Neuroscience       Date:  2008-03-07       Impact factor: 3.590

Review 6.  Donald Munro Lecture. Spinal cord injury--past, present, and future.

Authors:  William H Donovan
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

7.  Reduced extracellular zinc levels facilitate glutamate-mediated oligodendrocyte death after trauma.

Authors:  Joshua T Johnstone; Paul D Morton; Arumugam R Jayakumar; Valerie Bracchi-Ricard; Erik Runko; Daniel J Liebl; Michael D Norenberg; John R Bethea
Journal:  J Neurosci Res       Date:  2013-03-29       Impact factor: 4.164

Review 8.  Opioid administration following spinal cord injury: implications for pain and locomotor recovery.

Authors:  Sarah A Woller; Michelle A Hook
Journal:  Exp Neurol       Date:  2013-03-15       Impact factor: 5.330

9.  The Sur1-Trpm4 Channel in Spinal Cord Injury.

Authors:  J Marc Simard; Seung Kyoon Woo; Bizhan Aarabi; Volodymyr Gerzanich
Journal:  J Spine       Date:  2013-08-17

Review 10.  Microdialysis in central nervous system disorders and their treatment.

Authors:  David J McAdoo; Ping Wu
Journal:  Pharmacol Biochem Behav       Date:  2008-03-10       Impact factor: 3.697

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.